一种有效的选择性 adenosine A1 receptor 拮抗剂,目前正在开发用于急性充血性心力衰竭和肾功能损害的演技。
Rolofylline, aslo known as KW-3902, is an experimental diuretic which acts as a selective adenosine A1 receptor antagonist. Development of rolofylline was terminated on September 1, 2009, after the results of a large clinical trial (PROTECT) showed the drug to be no better than placebo for patients with acute heart failure. Participants given rolofylline did show some improvement in shortness of breath, but the drug did not prevent kidney damage or have any significant effect on overall treatment success. Rolofylline was also associated with a higher incidence of seizures and stroke.